Literature DB >> 17539693

Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia.

Charles H Hennekens1.   

Abstract

Cardiovascular disease (CVD), which includes coronary heart, cerebrovascular, and peripheral vascular disease, is the leading cause of death in the United States and most developed countries, accounting for about 50% of all deaths. The major risk factors include obesity and its consequences, dyslipidemia, hypertension, insulin resistance leading to diabetes, and cigarette smoking. In developing countries, CVD will become the leading cause of death due to alarming increases in obesity, sedentary lifestyles, cigarette smoking, and improvements in prevention and treatment of malnutrition and infection. Compared with nonschizophrenics, patients with schizophrenia have a 20% shorter life expectancy (i.e., from 76 to 61 years). In general populations, about 1% die from suicide compared with about 10% among patients with schizophrenia (relative risk = 10). For CVD, the corresponding figures are 50% and about 75% (relative risk = 1.5). In patients with schizophrenia, however, CVD occurs more frequently and accounts for more premature deaths than suicide. Patients with schizophrenia have alarmingly higher rates of obesity, dyslipidemia, hypertension, diabetes, and cigarette smoking than nonschizophrenic individuals in the general population. Compounding these data, patients with schizophrenia have less access to medical care, consume less medical care, and are less compliant. Primary prevention strategies should include the choice of antipsychotic drug regimens that do not adversely affect the major risk factors for CVD.

Entities:  

Mesh:

Year:  2007        PMID: 17539693

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  37 in total

1.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

2.  Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia.

Authors:  Jimmi Nielsen; Rasmus Røge; Sofie Gry Pristed; Anne Grethe Viuff; Henrik Ullum; Lise Wegner Thørner; Thomas Werge; Torkel Vang
Journal:  Schizophr Bull       Date:  2014-08-25       Impact factor: 9.306

Review 3.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

4.  An adjunct exercise program for serious mental illness: who chooses to participate and is it feasible?

Authors:  Louisa G Sylvia; Lynne Kopeski; Carrie Brown; Paula Bolton; Corina Laudate; Gina DiGangi; Paula Martin; James A Reid; Jules C Martowski; Amy Meade; Ingrid A Sarmiento; Jianping Wang; Angela C Utschig; Arthur Siegel; Edmund C Neuhaus
Journal:  Community Ment Health J       Date:  2012-10-13

5.  Psychiatrists' approach to vascular risk assessment in Latin America.

Authors:  Pablo Richly; Pablo López; Ezequiel Gleichgerrcht; Daniel Flichtentrei; María Prats; Ricardo Mastandueno; Julián Bustin; Marcelo Cetkovich-Bakmas
Journal:  World J Psychiatry       Date:  2014-09-22

Review 6.  Cariprazine for Schizophrenia and Bipolar Disorder.

Authors:  Jonathan R Scarff
Journal:  Innov Clin Neurosci       Date:  2016-10-01

Review 7.  [Stress, mental disorders and coronary heart disease].

Authors:  F Lederbogen; A Ströhle
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

Review 8.  Inequalities in healthcare provision for people with severe mental illness.

Authors:  David Lawrence; Stephen Kisely
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153

9.  Quality of care for cardiovascular disease-related conditions in patients with and without mental disorders.

Authors:  Amy M Kilbourne; Deborah Welsh; John F McCarthy; Edward P Post; Frederic C Blow
Journal:  J Gen Intern Med       Date:  2008-07-15       Impact factor: 5.128

Review 10.  Brexpiprazole: A New Treatment Option for Schizophrenia.

Authors:  Jonathan R Scarff
Journal:  Innov Clin Neurosci       Date:  2016-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.